PACRA Maintains the Entity Ratings of Ferozsons Laboratories Limited

Ferozsons Laboratories Limited (hereafter referred to as “Ferozsons” or “the Company”) is primarily engaged in the manufacturing and sale of pharmaceutical products, alongside the import and distribution of medical devices. The Company operates across more than 100 brands spanning specialized therapeutic areas, including gastroenterology, hepatology, cardiology, diabetes, metabolic health, dermatology, and pediatrics, reflecting a deliberate focus on both acute care (~60%) and chronic therapies (~40%). Its manufacturing facility is cGMP-compliant, underpinning the quality standards central to its product offering. Ferozsons has cultivated meaningful international partnerships, including with Gilead Sciences Inc. for pharmaceuticals and Boston Scientific (USA) and Nihon Kohden for medical devices, which have broadened its revenue base beyond its core medicines portfolio. Leading brands such as Omega, Carveda, Xavor, and Esomega anchor its commercial position. The Company’s strategic investment in BF Biosciences Limited, a next-phase pioneer biotech facility focused on biological and non-biological injectable medicines, further extends its positioning toward the emerging frontier of pharmaceutical development in Pakistan. Pakistan’s pharmaceutical sector continues to demonstrate strong resilience and structural expansion, characterized by an overall industry growth of 15.2% on a Moving Annual Total (MAT) basis, reaching a total valuation of PKR 1.2 trillion by January 2026. This trajectory is underpinned by a 5-year MAT CAGR of 17.2%, driven by a large and expanding population base, rising prevalence of chronic and infectious diseases, and improving healthcare access. The sector has demonstrated steady momentum, with double-digit growth primarily supported by pricing adjustments following regulatory relaxation on non-essential medicines. While the industry remains moderately concentrated at the top, it is characterized by intense competition and a long tail of fragmented players, with local manufacturers increasingly gaining share from multinational companies due to cost competitiveness and strong branded-generic portfolios. The sector’s profitability has rebounded, driven by pricing flexibility, easing input cost pressures, and operating leverage; however, risks persist in the form of high dependence on imported APIs, exposure to PKR volatility, regulatory constraints on essential medicines, and evolving global supply chain disruptions. Going forward, the sector is expected to maintain its growth trajectory, supported by favorable demographics, low per capita drug consumption, and export potential, although sustained performance will hinge on macroeconomic stability, regulatory consistency, and supply chain resilience. During 1HFY26, Ferozsons Laboratories Limited recorded consolidated sales of PKR 12,622mln, with an annualized growth rate of ~33.9%, driven primarily by volume expansion in the generic drug segment. On a standalone basis, the Company’s topline grew by ~18% over the same period last year (FY25: ~9% growth) and recorded a bottom-line of ~PKR 354mln (FY25: ~PKR 528mln). Ferozsons’ financial risk profile is characterized by strong coverage ratios and cash flow generation, though it faces a stretched working capital cycle. The capital structure is moderately leveraged, with borrowings primarily consisting of short-term debt to finance working capital requirements.
The ratings are dependent on the sustainability of the growth trajectory in the topline and profitability matrix on both a consolidated and standalone basis. The adequacy of cash flows and improvement in the working capital cycle remain imperative. Furthermore, the alignment with the performance indicators, as illustrated in the shared financial projections, will continue to be paramount.

About the Entity
Ferozsons Laboratories Limited is a publicly listed company operating in Pakistan’s pharmaceutical sector since 1956. The sponsoring family holds ~48% ownership in the Company. The Board of Directors comprises seven members, including four non-executive, two independent, and one executive director. Mrs. Akhter Khalid Waheed serves as the Chairperson, while Mr. Osman Khalid Waheed holds the position of Chief Executive Officer.